threonine has been researched along with imatinib mesylate in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Blencke, S; Daub, H; Ullrich, A | 1 |
| Kakihana, K; Kurosu, T; Miura, O; Mizuchi, D; Yamamoto, M | 1 |
| Fermeglia, M; Ferrone, M; Pricl, S; Tamborini, E | 1 |
| Tuma, RS | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Soverini, S | 1 |
| Albitar, M; Cortes, J; Giles, F; Kantarjian, H; Lee, TS; Potts, SJ | 1 |
| Fermeglia, M; Greco, A; Negri, T; Pavan, GM; Pierotti, MA; Pilotti, S; Pricl, S; Sandri, M; Tamborini, E; Virdis, E | 1 |
| Aitken, RJ; Baker, MA; Curry, B; Hetherington, L | 1 |
| Adamia, S; Azam, M; Barrett, R; Cameron, M; Choi, HG; Debiec-Rychter, M; Fletcher, JA; Gray, N; Griffin, JD; Janne, PA; Khosravi-Far, R; Kung, AL; Manley, PW; Mayeda, M; Melo, JV; Moreno, D; Ray, A; Seeliger, M; Sim, T; Weisberg, E; Wu, C; Zhang, J; Zhou, W | 1 |
| Ding, K; Leng, F; Li, Y; Long, H; Lu, X; Luo, J; Pan, X; Ren, X; Shen, M; Tu, Z; Wen, D; Zhang, F; Zhang, Z | 1 |
| Beadling, C; Bertagnolli, MM; Corless, CL; Demetri, GD; Fletcher, JA; Heinrich, MC; Lee, JC; Mariño-Enríquez, A; Morgan, JA; Ravegnini, G; Serrano, C; Wang, Y | 1 |
| Ji, C; Li, P; Liu, N; Liu, Q; Ma, D; Sun, X; Zang, S | 1 |
| Digumarti, R; Gundeti, S; Kagita, S; Uppalapati, S | 1 |
| Bardaweel, SK; El-Abadelah, MM; Habashneh, AY; Taha, MO | 1 |
| Chantepie, S; Damaj, G; Decamp, M; Henry, A; Hueso, T; Johnson-Ansah, H; Maitre, E; Mensi, S; Vilque, JP | 1 |
| Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A | 1 |
16 other study(ies) available for threonine and imatinib mesylate
| Article | Year |
|---|---|
Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Threonine; Transfection | 2003 |
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Topics: Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leukemia; Milk Proteins; Mutation; Phosphorylation; Piperazines; Protein Structure, Tertiary; Pyrimidines; STAT5 Transcription Factor; Threonine; Trans-Activators | 2004 |
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Topics: Antineoplastic Agents; Benzamides; Computational Biology; Computer Simulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Threonine | 2005 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat | 2007 |
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Computer Simulation; Crystallography; Drug Resistance, Neoplasm; Genes, abl; Glutamic Acid; Humans; Imatinib Mesylate; Isoleucine; Methionine; Models, Molecular; Molecular Biology; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein-Tyrosine Kinases; Pyrimidines; Static Electricity; Threonine | 2008 |
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Research Design; Threonine | 2009 |
Phosphorylation and consequent stimulation of the tyrosine kinase c-Abl by PKA in mouse spermatozoa; its implications during capacitation.
Topics: Animals; Benzamides; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Flagella; Imatinib Mesylate; Male; Mice; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Sperm Capacitation; Spermatozoa; Threonine; Tyrosine | 2009 |
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Molecular Structure; Mutant Proteins; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; src-Family Kinases; Thiazoles; Threonine | 2010 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Threonine | 2012 |
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
Topics: Antineoplastic Agents; Arginine; Benzamides; Carcinoma; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinase; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Sequence Analysis, DNA; Signal Transduction; Stomach Neoplasms; Threonine; Time Factors; TOR Serine-Threonine Kinases | 2015 |
Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Cell Differentiation; Down-Regulation; Drug Resistance, Neoplasm; Erythroid Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Phosphorylation; Proteolysis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Threonine | 2015 |
Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Threonine | 2015 |
Synthesis and Structure-Activity Relationship; Exploration of some Potent Anti-Cancer Phenyl Amidrazone Derivatives.
Topics: Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Hydrazones; Hydrogen Bonding; Imatinib Mesylate; Ligands; Molecular Docking Simulation; Piperazines; Protein Binding; Structure-Activity Relationship; Threonine | 2018 |
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Topics: Amino Acid Substitution; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation, Missense; Myeloproliferative Disorders; Neoadjuvant Therapy; Receptors, Colony-Stimulating Factor; Threonine; Transplantation, Homologous; Treatment Outcome | 2019 |
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays | 2020 |